BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 23-Dec-2020

The Company has informed that it has credited the Bonus shares for the year ended on June 30, 2020 to the respective shareholders' BO Accounts on December 23, 2020.

SQURPHARMA 22-Nov-2020

Trading of the shares of the Company will resume on 23.11.2020 after record date.

SQURPHARMA 18-Nov-2020

(Continuation news of SQURPHARMA): Note 8- SHORT TERM LOAN (Unsecured): Balance of Short Term Loan (Unsecured) as at 30 June 2020 was BDT 4,885,090,120 and as at 30 June 2019 was BDT 2,937,071,066. This loan consists of loan given to Square Textiles Ltd, Square Fashions Ltd., Square Hospitals Ltd., Square Lifesciences Ltd.(end)

SQURPHARMA 18-Nov-2020

The auditor of the Square Pharmaceuticals Ltd has given the "Emphasis of Matter " paragraph in the Auditor's Report for the year ended on 30 June 2020. Emphasis of Matter: We draw attention to the note no. 8 to the separate financial statements, which describes the loans given to subsidiaries and associates as well as companies with common directors. The company obtained approval for such loans from the Board of Directors. Our opinion is not modified in this regard. (cont.)

SQURPHARMA 17-Nov-2020

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 18.11.2020 to 19.11.2020. Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2020.

SQURPHARMA 12-Nov-2020

(Q1 Un-audited): Consolidated EPS was Tk. 4.66 for July-September 2020 as against Tk. 3.97 for July-September 2019; Consolidated NOCFPS was Tk. 3.47 for July-September 2020 as against Tk. 3.87 for July-September 2019. Consolidated NAV per share was Tk. 97.13 as on September 30, 2020 and Tk. 91.57 as on June 30, 2020.

SQURPHARMA 09-Nov-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.

SQURPHARMA 25-Oct-2020

There will be no price limit on the trading of the shares of the Company today (25.10.2020) following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.

SQURPHARMA 25-Oct-2020

(Continuation news of SQURPHARMA): ii) Bonus share is declared out of accumulated profit. iii) Bonus share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post dividend retained earnings become negative or a debit balance. (end)

SQURPHARMA 25-Oct-2020

(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 15.82, Consolidated NAV per share of Tk. 91.57 and Consolidated NOCFPS of Tk. 12.75 for the year ended on June 30, 2020 as against Tk. 14.98, Tk. 80.40 and Tk. 14.68 respectively for the same period of the previous year. The Company also informed that i) Bonus shares has been recommended in view to utilize its retained amount as capital for business expansion. (cont.2)

Previous Next page